nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—sarcoma	0.436	1	CtDrD
Gefitinib—EGFR—sarcoma	0.23	1	CbGaD
Gefitinib—CYP1A1—Dacarbazine—sarcoma	0.0233	0.141	CbGbCtD
Gefitinib—ABCG2—Dactinomycin—sarcoma	0.0218	0.133	CbGbCtD
Gefitinib—ABCG2—Mitoxantrone—sarcoma	0.0196	0.119	CbGbCtD
Gefitinib—ABCG2—Vincristine—sarcoma	0.0135	0.0817	CbGbCtD
Gefitinib—ABCG2—Etoposide—sarcoma	0.0123	0.0749	CbGbCtD
Gefitinib—CYP3A4—Thiotepa—sarcoma	0.00982	0.0597	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—sarcoma	0.00841	0.0511	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—sarcoma	0.00788	0.0478	CbGbCtD
Gefitinib—CYP3A5—Vincristine—sarcoma	0.00745	0.0453	CbGbCtD
Gefitinib—ABCB1—Mitoxantrone—sarcoma	0.00705	0.0428	CbGbCtD
Gefitinib—CYP3A5—Etoposide—sarcoma	0.00683	0.0415	CbGbCtD
Gefitinib—STK10—renal vein—sarcoma	0.00614	0.151	CbGeAlD
Gefitinib—ABCB1—Vincristine—sarcoma	0.00485	0.0295	CbGbCtD
Gefitinib—ABCB1—Etoposide—sarcoma	0.00445	0.027	CbGbCtD
Gefitinib—CYP3A4—Mitoxantrone—sarcoma	0.00422	0.0256	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—sarcoma	0.00303	0.0184	CbGbCtD
Gefitinib—CYP3A4—Vincristine—sarcoma	0.00291	0.0176	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—sarcoma	0.00286	0.0173	CbGbCtD
Gefitinib—CYP3A4—Etoposide—sarcoma	0.00266	0.0162	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—sarcoma	0.00182	0.011	CbGbCtD
Gefitinib—CHEK2—myometrium—sarcoma	0.000822	0.0203	CbGeAlD
Gefitinib—EGFR—mammary gland—sarcoma	0.000764	0.0188	CbGeAlD
Gefitinib—CSNK1E—mammary gland—sarcoma	0.000734	0.0181	CbGeAlD
Gefitinib—ERBB3—mammary gland—sarcoma	0.000709	0.0175	CbGeAlD
Gefitinib—MKNK2—mammary gland—sarcoma	0.000674	0.0166	CbGeAlD
Gefitinib—MKNK1—mammary gland—sarcoma	0.000665	0.0164	CbGeAlD
Gefitinib—Lapatinib—EGFR—sarcoma	0.00056	0.148	CrCbGaD
Gefitinib—SBK1—tendon—sarcoma	0.000536	0.0132	CbGeAlD
Gefitinib—Vandetanib—TEK—sarcoma	0.000529	0.139	CrCbGaD
Gefitinib—CSNK1E—myometrium—sarcoma	0.000521	0.0129	CbGeAlD
Gefitinib—IRAK4—myometrium—sarcoma	0.000513	0.0127	CbGeAlD
Gefitinib—ERBB3—embryo—sarcoma	0.000484	0.0119	CbGeAlD
Gefitinib—MKNK2—myometrium—sarcoma	0.000478	0.0118	CbGeAlD
Gefitinib—MKNK1—myometrium—sarcoma	0.000472	0.0116	CbGeAlD
Gefitinib—CSNK1E—seminal vesicle—sarcoma	0.000471	0.0116	CbGeAlD
Gefitinib—CHEK2—tendon—sarcoma	0.000467	0.0115	CbGeAlD
Gefitinib—IRAK4—seminal vesicle—sarcoma	0.000463	0.0114	CbGeAlD
Gefitinib—CHEK2—bone marrow—sarcoma	0.000453	0.0112	CbGeAlD
Gefitinib—SBK1—testis—sarcoma	0.000444	0.011	CbGeAlD
Gefitinib—IRAK4—hematopoietic system—sarcoma	0.000441	0.0109	CbGeAlD
Gefitinib—HIPK4—testis—sarcoma	0.000439	0.0108	CbGeAlD
Gefitinib—MKNK2—seminal vesicle—sarcoma	0.000432	0.0107	CbGeAlD
Gefitinib—ERBB3—hematopoietic system—sarcoma	0.000432	0.0107	CbGeAlD
Gefitinib—ERBB3—connective tissue—sarcoma	0.000416	0.0103	CbGeAlD
Gefitinib—MKNK2—hematopoietic system—sarcoma	0.000411	0.0101	CbGeAlD
Gefitinib—IRAK1—hematopoietic system—sarcoma	0.000411	0.0101	CbGeAlD
Gefitinib—MKNK1—hematopoietic system—sarcoma	0.000405	0.01	CbGeAlD
Gefitinib—Afatinib—EGFR—sarcoma	0.000397	0.105	CrCbGaD
Gefitinib—CHEK2—Vindesine—Vincristine—sarcoma	0.000395	0.181	CbGdCrCtD
Gefitinib—MKNK2—connective tissue—sarcoma	0.000395	0.00975	CbGeAlD
Gefitinib—CSNK1E—skin of body—sarcoma	0.000389	0.0096	CbGeAlD
Gefitinib—STK10—myometrium—sarcoma	0.000389	0.00959	CbGeAlD
Gefitinib—CHEK2—testis—sarcoma	0.000387	0.00954	CbGeAlD
Gefitinib—ERBB3—skin of body—sarcoma	0.000375	0.00926	CbGeAlD
Gefitinib—ERBB3—Podofilox—Etoposide—sarcoma	0.000369	0.169	CbGdCrCtD
Gefitinib—MKNK2—smooth muscle tissue—sarcoma	0.000362	0.00892	CbGeAlD
Gefitinib—IRAK1—smooth muscle tissue—sarcoma	0.000362	0.00892	CbGeAlD
Gefitinib—EGFR—uterus—sarcoma	0.000352	0.00867	CbGeAlD
Gefitinib—ALB—mammary gland—sarcoma	0.000348	0.00859	CbGeAlD
Gefitinib—MAP2K5—myometrium—sarcoma	0.000347	0.00857	CbGeAlD
Gefitinib—EPHA6—testis—sarcoma	0.000347	0.00856	CbGeAlD
Gefitinib—Vandetanib—PDGFRB—sarcoma	0.000341	0.0898	CrCbGaD
Gefitinib—CSNK1E—uterus—sarcoma	0.000338	0.00834	CbGeAlD
Gefitinib—STK10—hematopoietic system—sarcoma	0.000334	0.00824	CbGeAlD
Gefitinib—ERBB3—uterus—sarcoma	0.000326	0.00805	CbGeAlD
Gefitinib—SBK1—lymph node—sarcoma	0.000322	0.00794	CbGeAlD
Gefitinib—Bosutinib—PDGFRB—sarcoma	0.000319	0.084	CrCbGaD
Gefitinib—MAP3K19—testis—sarcoma	0.000315	0.00778	CbGeAlD
Gefitinib—MAP2K5—seminal vesicle—sarcoma	0.000314	0.00774	CbGeAlD
Gefitinib—MKNK2—cardiac atrium—sarcoma	0.000312	0.00769	CbGeAlD
Gefitinib—MKNK2—uterus—sarcoma	0.00031	0.00765	CbGeAlD
Gefitinib—IRAK4—lymphoid tissue—sarcoma	0.00031	0.00765	CbGeAlD
Gefitinib—MKNK1—cardiac atrium—sarcoma	0.000308	0.00759	CbGeAlD
Gefitinib—ERBB3—lymphoid tissue—sarcoma	0.000304	0.0075	CbGeAlD
Gefitinib—CSNK1E—tendon—sarcoma	0.000296	0.00731	CbGeAlD
Gefitinib—IRAK4—tendon—sarcoma	0.000292	0.00719	CbGeAlD
Gefitinib—MKNK2—lymphoid tissue—sarcoma	0.000289	0.00713	CbGeAlD
Gefitinib—MKNK1—lymphoid tissue—sarcoma	0.000285	0.00704	CbGeAlD
Gefitinib—IRAK4—bone marrow—sarcoma	0.000282	0.00697	CbGeAlD
Gefitinib—Erlotinib—EGFR—sarcoma	0.00028	0.0739	CrCbGaD
Gefitinib—CHEK2—lymph node—sarcoma	0.00028	0.00692	CbGeAlD
Gefitinib—Vandetanib—SRC—sarcoma	0.000275	0.0725	CrCbGaD
Gefitinib—MKNK2—tendon—sarcoma	0.000272	0.0067	CbGeAlD
Gefitinib—IRAK1—tendon—sarcoma	0.000272	0.0067	CbGeAlD
Gefitinib—MKNK2—bone marrow—sarcoma	0.000263	0.00649	CbGeAlD
Gefitinib—IRAK1—bone marrow—sarcoma	0.000263	0.00649	CbGeAlD
Gefitinib—MKNK1—bone marrow—sarcoma	0.00026	0.00641	CbGeAlD
Gefitinib—Vandetanib—KDR—sarcoma	0.000258	0.0681	CrCbGaD
Gefitinib—Bosutinib—SRC—sarcoma	0.000257	0.0678	CrCbGaD
Gefitinib—EGFR—testis—sarcoma	0.000255	0.00629	CbGeAlD
Gefitinib—ERBB3—Vinblastine—Vincristine—sarcoma	0.000254	0.116	CbGdCrCtD
Gefitinib—STK10—uterus—sarcoma	0.000252	0.00622	CbGeAlD
Gefitinib—CHEK2—Vinorelbine—Vincristine—sarcoma	0.000249	0.114	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—sarcoma	0.000249	0.114	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—sarcoma	0.000249	0.114	CbGdCrCtD
Gefitinib—CSNK1E—testis—sarcoma	0.000245	0.00605	CbGeAlD
Gefitinib—ORM1—hematopoietic system—sarcoma	0.000242	0.00597	CbGeAlD
Gefitinib—IRAK4—testis—sarcoma	0.000241	0.00596	CbGeAlD
Gefitinib—EGFR—liver—sarcoma	0.000241	0.00595	CbGeAlD
Gefitinib—ERBB3—testis—sarcoma	0.000237	0.00584	CbGeAlD
Gefitinib—STK10—lymphoid tissue—sarcoma	0.000235	0.0058	CbGeAlD
Gefitinib—CSNK1E—liver—sarcoma	0.000232	0.00572	CbGeAlD
Gefitinib—IRAK4—liver—sarcoma	0.000228	0.00563	CbGeAlD
Gefitinib—MAP2K5—cardiac atrium—sarcoma	0.000226	0.00558	CbGeAlD
Gefitinib—MKNK2—testis—sarcoma	0.000225	0.00555	CbGeAlD
Gefitinib—IRAK1—testis—sarcoma	0.000225	0.00555	CbGeAlD
Gefitinib—ERBB3—liver—sarcoma	0.000224	0.00552	CbGeAlD
Gefitinib—MKNK1—testis—sarcoma	0.000222	0.00548	CbGeAlD
Gefitinib—STK10—tendon—sarcoma	0.000221	0.00545	CbGeAlD
Gefitinib—Vandetanib—VEGFA—sarcoma	0.000219	0.0577	CrCbGaD
Gefitinib—CYP2C9—mammary gland—sarcoma	0.000217	0.00536	CbGeAlD
Gefitinib—STK10—bone marrow—sarcoma	0.000214	0.00528	CbGeAlD
Gefitinib—MKNK2—liver—sarcoma	0.000213	0.00525	CbGeAlD
Gefitinib—IRAK1—liver—sarcoma	0.000213	0.00525	CbGeAlD
Gefitinib—MKNK1—liver—sarcoma	0.00021	0.00518	CbGeAlD
Gefitinib—MAP2K5—tendon—sarcoma	0.000197	0.00487	CbGeAlD
Gefitinib—EGFR—lymph node—sarcoma	0.000185	0.00456	CbGeAlD
Gefitinib—Vandetanib—EGFR—sarcoma	0.000185	0.0487	CrCbGaD
Gefitinib—STK10—testis—sarcoma	0.000183	0.00451	CbGeAlD
Gefitinib—CSNK1E—lymph node—sarcoma	0.000178	0.00438	CbGeAlD
Gefitinib—IRAK4—lymph node—sarcoma	0.000175	0.00432	CbGeAlD
Gefitinib—STK10—liver—sarcoma	0.000173	0.00427	CbGeAlD
Gefitinib—Bosutinib—EGFR—sarcoma	0.000173	0.0456	CrCbGaD
Gefitinib—CHEK2—Vinblastine—Vincristine—sarcoma	0.000172	0.0784	CbGdCrCtD
Gefitinib—ERBB3—lymph node—sarcoma	0.000172	0.00423	CbGeAlD
Gefitinib—CYP2C19—hematopoietic system—sarcoma	0.000171	0.00422	CbGeAlD
Gefitinib—ABCG2—myometrium—sarcoma	0.000169	0.00417	CbGeAlD
Gefitinib—MAP2K5—testis—sarcoma	0.000163	0.00403	CbGeAlD
Gefitinib—IRAK1—lymph node—sarcoma	0.000163	0.00402	CbGeAlD
Gefitinib—MKNK2—lymph node—sarcoma	0.000163	0.00402	CbGeAlD
Gefitinib—MKNK1—lymph node—sarcoma	0.000161	0.00397	CbGeAlD
Gefitinib—ORM1—bone marrow—sarcoma	0.000155	0.00383	CbGeAlD
Gefitinib—MAP2K5—liver—sarcoma	0.000154	0.00381	CbGeAlD
Gefitinib—ABCG2—seminal vesicle—sarcoma	0.000153	0.00376	CbGeAlD
Gefitinib—CYP1A1—hematopoietic system—sarcoma	0.000138	0.0034	CbGeAlD
Gefitinib—CYP3A5—hematopoietic system—sarcoma	0.000135	0.00332	CbGeAlD
Gefitinib—STK10—lymph node—sarcoma	0.000133	0.00327	CbGeAlD
Gefitinib—CYP2C9—hematopoietic system—sarcoma	0.000133	0.00327	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—sarcoma	0.00013	0.0594	CbGdCrCtD
Gefitinib—ORM1—liver—sarcoma	0.000125	0.00309	CbGeAlD
Gefitinib—Urethral disorder—Etoposide—sarcoma	0.000121	0.00208	CcSEcCtD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—sarcoma	0.00012	0.055	CbGdCrCtD
Gefitinib—Infection—Dactinomycin—sarcoma	0.00012	0.00207	CcSEcCtD
Gefitinib—CYP1A1—skin of body—sarcoma	0.00012	0.00295	CbGeAlD
Gefitinib—Nervous system disorder—Thiotepa—sarcoma	0.00012	0.00206	CcSEcCtD
Gefitinib—Thrombocytopenia—Thiotepa—sarcoma	0.000119	0.00205	CcSEcCtD
Gefitinib—Anaemia—Mitoxantrone—sarcoma	0.000119	0.00205	CcSEcCtD
Gefitinib—Thrombocytopenia—Dactinomycin—sarcoma	0.000119	0.00204	CcSEcCtD
Gefitinib—Skin disorder—Thiotepa—sarcoma	0.000118	0.00204	CcSEcCtD
Gefitinib—MAP2K5—lymph node—sarcoma	0.000118	0.00292	CbGeAlD
Gefitinib—Dry eye—Doxorubicin—sarcoma	0.000118	0.00202	CcSEcCtD
Gefitinib—Erythema multiforme—Etoposide—sarcoma	0.000117	0.002	CcSEcCtD
Gefitinib—Malaise—Mitoxantrone—sarcoma	0.000116	0.002	CcSEcCtD
Gefitinib—ALB—testis—sarcoma	0.000116	0.00287	CbGeAlD
Gefitinib—Anorexia—Thiotepa—sarcoma	0.000116	0.002	CcSEcCtD
Gefitinib—Thrombophlebitis—Epirubicin—sarcoma	0.000115	0.00198	CcSEcCtD
Gefitinib—Anorexia—Dactinomycin—sarcoma	0.000115	0.00198	CcSEcCtD
Gefitinib—Eye disorder—Etoposide—sarcoma	0.000115	0.00198	CcSEcCtD
Gefitinib—Bladder pain—Doxorubicin—sarcoma	0.000115	0.00198	CcSEcCtD
Gefitinib—Mouth ulceration—Doxorubicin—sarcoma	0.000115	0.00198	CcSEcCtD
Gefitinib—Cardiac disorder—Etoposide—sarcoma	0.000114	0.00197	CcSEcCtD
Gefitinib—Cough—Mitoxantrone—sarcoma	0.000113	0.00194	CcSEcCtD
Gefitinib—Angiopathy—Etoposide—sarcoma	0.000112	0.00192	CcSEcCtD
Gefitinib—Hepatic failure—Epirubicin—sarcoma	0.000111	0.00191	CcSEcCtD
Gefitinib—Mediastinal disorder—Etoposide—sarcoma	0.000111	0.00191	CcSEcCtD
Gefitinib—Eye pain—Epirubicin—sarcoma	0.000111	0.0019	CcSEcCtD
Gefitinib—ALB—liver—sarcoma	0.00011	0.00271	CbGeAlD
Gefitinib—ABCG2—uterus—sarcoma	0.00011	0.0027	CbGeAlD
Gefitinib—Alopecia—Etoposide—sarcoma	0.000109	0.00187	CcSEcCtD
Gefitinib—Infection—Vincristine—sarcoma	0.000107	0.00185	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—sarcoma	0.000107	0.00184	CcSEcCtD
Gefitinib—Nervous system disorder—Vincristine—sarcoma	0.000106	0.00182	CcSEcCtD
Gefitinib—Decreased appetite—Thiotepa—sarcoma	0.000106	0.00182	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—sarcoma	0.000106	0.00182	CcSEcCtD
Gefitinib—Thrombocytopenia—Vincristine—sarcoma	0.000106	0.00182	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000105	0.00181	CcSEcCtD
Gefitinib—Decreased appetite—Dactinomycin—sarcoma	0.000105	0.00181	CcSEcCtD
Gefitinib—Fatigue—Thiotepa—sarcoma	0.000105	0.00181	CcSEcCtD
Gefitinib—Infection—Mitoxantrone—sarcoma	0.000105	0.0018	CcSEcCtD
Gefitinib—CYP1A1—cardiac atrium—sarcoma	0.000105	0.00258	CbGeAlD
Gefitinib—Dermatitis bullous—Epirubicin—sarcoma	0.000105	0.0018	CcSEcCtD
Gefitinib—Fatigue—Dactinomycin—sarcoma	0.000104	0.00179	CcSEcCtD
Gefitinib—Pain—Thiotepa—sarcoma	0.000104	0.00179	CcSEcCtD
Gefitinib—Constipation—Thiotepa—sarcoma	0.000104	0.00179	CcSEcCtD
Gefitinib—CYP1A1—uterus—sarcoma	0.000104	0.00257	CbGeAlD
Gefitinib—Shock—Mitoxantrone—sarcoma	0.000104	0.00178	CcSEcCtD
Gefitinib—Pain—Dactinomycin—sarcoma	0.000103	0.00178	CcSEcCtD
Gefitinib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000103	0.00177	CcSEcCtD
Gefitinib—Anorexia—Vincristine—sarcoma	0.000103	0.00177	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—sarcoma	0.000103	0.00177	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—sarcoma	0.000102	0.00176	CcSEcCtD
Gefitinib—Skin disorder—Mitoxantrone—sarcoma	0.000102	0.00176	CcSEcCtD
Gefitinib—Hypotension—Vincristine—sarcoma	0.000101	0.00174	CcSEcCtD
Gefitinib—CYP3A4—hematopoietic system—sarcoma	0.000101	0.00249	CbGeAlD
Gefitinib—Anorexia—Mitoxantrone—sarcoma	0.0001	0.00173	CcSEcCtD
Gefitinib—Gastrointestinal pain—Thiotepa—sarcoma	9.97e-05	0.00171	CcSEcCtD
Gefitinib—CYP2D6—hematopoietic system—sarcoma	9.94e-05	0.00245	CbGeAlD
Gefitinib—Anaemia—Etoposide—sarcoma	9.92e-05	0.00171	CcSEcCtD
Gefitinib—Gastrointestinal pain—Dactinomycin—sarcoma	9.9e-05	0.0017	CcSEcCtD
Gefitinib—Hypotension—Mitoxantrone—sarcoma	9.84e-05	0.00169	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—sarcoma	9.8e-05	0.00168	CcSEcCtD
Gefitinib—Urticaria—Thiotepa—sarcoma	9.69e-05	0.00167	CcSEcCtD
Gefitinib—Malaise—Etoposide—sarcoma	9.68e-05	0.00166	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—sarcoma	9.67e-05	0.00166	CcSEcCtD
Gefitinib—Body temperature increased—Thiotepa—sarcoma	9.64e-05	0.00166	CcSEcCtD
Gefitinib—Abdominal pain—Thiotepa—sarcoma	9.64e-05	0.00166	CcSEcCtD
Gefitinib—ORM1—lymph node—sarcoma	9.62e-05	0.00237	CbGeAlD
Gefitinib—Abdominal pain—Dactinomycin—sarcoma	9.57e-05	0.00165	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—sarcoma	9.57e-05	0.00165	CcSEcCtD
Gefitinib—Decreased appetite—Vincristine—sarcoma	9.4e-05	0.00162	CcSEcCtD
Gefitinib—Dyspnoea—Mitoxantrone—sarcoma	9.39e-05	0.00161	CcSEcCtD
Gefitinib—Cough—Etoposide—sarcoma	9.37e-05	0.00161	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Vincristine—sarcoma	9.34e-05	0.00161	CcSEcCtD
Gefitinib—Fatigue—Vincristine—sarcoma	9.32e-05	0.0016	CcSEcCtD
Gefitinib—ABCG2—bone marrow—sarcoma	9.3e-05	0.00229	CbGeAlD
Gefitinib—Dehydration—Epirubicin—sarcoma	9.29e-05	0.0016	CcSEcCtD
Gefitinib—Constipation—Vincristine—sarcoma	9.25e-05	0.00159	CcSEcCtD
Gefitinib—Pain—Vincristine—sarcoma	9.25e-05	0.00159	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—sarcoma	9.16e-05	0.00157	CcSEcCtD
Gefitinib—Decreased appetite—Mitoxantrone—sarcoma	9.15e-05	0.00157	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—sarcoma	9.09e-05	0.00156	CcSEcCtD
Gefitinib—Fatigue—Mitoxantrone—sarcoma	9.08e-05	0.00156	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	9.07e-05	0.00156	CcSEcCtD
Gefitinib—Pain—Mitoxantrone—sarcoma	9.01e-05	0.00155	CcSEcCtD
Gefitinib—Constipation—Mitoxantrone—sarcoma	9.01e-05	0.00155	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—sarcoma	9e-05	0.00155	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	9e-05	0.00155	CcSEcCtD
Gefitinib—Hypersensitivity—Thiotepa—sarcoma	8.98e-05	0.00154	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—sarcoma	8.92e-05	0.00153	CcSEcCtD
Gefitinib—CYP2C19—liver—sarcoma	8.85e-05	0.00218	CbGeAlD
Gefitinib—Gastrointestinal pain—Vincristine—sarcoma	8.84e-05	0.00152	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—sarcoma	8.81e-05	0.00152	CcSEcCtD
Gefitinib—Asthenia—Thiotepa—sarcoma	8.75e-05	0.0015	CcSEcCtD
Gefitinib—Infection—Etoposide—sarcoma	8.7e-05	0.0015	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—sarcoma	8.68e-05	0.00149	CcSEcCtD
Gefitinib—Pruritus—Thiotepa—sarcoma	8.63e-05	0.00148	CcSEcCtD
Gefitinib—Gastrointestinal pain—Mitoxantrone—sarcoma	8.61e-05	0.00148	CcSEcCtD
Gefitinib—Dehydration—Doxorubicin—sarcoma	8.6e-05	0.00148	CcSEcCtD
Gefitinib—Thrombocytopenia—Etoposide—sarcoma	8.58e-05	0.00147	CcSEcCtD
Gefitinib—Abdominal pain—Vincristine—sarcoma	8.55e-05	0.00147	CcSEcCtD
Gefitinib—Body temperature increased—Vincristine—sarcoma	8.55e-05	0.00147	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—sarcoma	8.51e-05	0.00146	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—sarcoma	8.47e-05	0.00146	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—sarcoma	8.47e-05	0.00146	CcSEcCtD
Gefitinib—ALB—lymph node—sarcoma	8.43e-05	0.00208	CbGeAlD
Gefitinib—Hypokalaemia—Doxorubicin—sarcoma	8.41e-05	0.00145	CcSEcCtD
Gefitinib—Urticaria—Mitoxantrone—sarcoma	8.37e-05	0.00144	CcSEcCtD
Gefitinib—Anorexia—Etoposide—sarcoma	8.35e-05	0.00144	CcSEcCtD
Gefitinib—Diarrhoea—Thiotepa—sarcoma	8.34e-05	0.00143	CcSEcCtD
Gefitinib—ABCB1—myometrium—sarcoma	8.33e-05	0.00205	CbGeAlD
Gefitinib—Body temperature increased—Mitoxantrone—sarcoma	8.32e-05	0.00143	CcSEcCtD
Gefitinib—Abdominal pain—Mitoxantrone—sarcoma	8.32e-05	0.00143	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	8.32e-05	0.00143	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—sarcoma	8.32e-05	0.00143	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—sarcoma	8.28e-05	0.00142	CcSEcCtD
Gefitinib—Hypotension—Etoposide—sarcoma	8.19e-05	0.00141	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	8.15e-05	0.0014	CcSEcCtD
Gefitinib—ABCB1—embryo—sarcoma	8.01e-05	0.00198	CbGeAlD
Gefitinib—Hypersensitivity—Vincristine—sarcoma	7.97e-05	0.00137	CcSEcCtD
Gefitinib—ABCG2—testis—sarcoma	7.95e-05	0.00196	CbGeAlD
Gefitinib—Pancreatitis—Doxorubicin—sarcoma	7.83e-05	0.00135	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—sarcoma	7.81e-05	0.00134	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—sarcoma	7.81e-05	0.00134	CcSEcCtD
Gefitinib—Hypersensitivity—Mitoxantrone—sarcoma	7.76e-05	0.00133	CcSEcCtD
Gefitinib—Asthenia—Vincristine—sarcoma	7.76e-05	0.00133	CcSEcCtD
Gefitinib—Vomiting—Thiotepa—sarcoma	7.75e-05	0.00133	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—sarcoma	7.74e-05	0.00133	CcSEcCtD
Gefitinib—Infestation—Epirubicin—sarcoma	7.7e-05	0.00132	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—sarcoma	7.7e-05	0.00132	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—sarcoma	7.7e-05	0.00132	CcSEcCtD
Gefitinib—Rash—Thiotepa—sarcoma	7.69e-05	0.00132	CcSEcCtD
Gefitinib—Dermatitis—Thiotepa—sarcoma	7.68e-05	0.00132	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—sarcoma	7.63e-05	0.00131	CcSEcCtD
Gefitinib—Rash—Dactinomycin—sarcoma	7.63e-05	0.00131	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—sarcoma	7.61e-05	0.00131	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—sarcoma	7.56e-05	0.0013	CcSEcCtD
Gefitinib—Asthenia—Mitoxantrone—sarcoma	7.56e-05	0.0013	CcSEcCtD
Gefitinib—Fatigue—Etoposide—sarcoma	7.55e-05	0.0013	CcSEcCtD
Gefitinib—ABCB1—seminal vesicle—sarcoma	7.53e-05	0.00186	CbGeAlD
Gefitinib—ABCG2—liver—sarcoma	7.51e-05	0.00185	CbGeAlD
Gefitinib—Stomatitis—Epirubicin—sarcoma	7.5e-05	0.00129	CcSEcCtD
Gefitinib—Constipation—Etoposide—sarcoma	7.49e-05	0.00129	CcSEcCtD
Gefitinib—Pain—Etoposide—sarcoma	7.49e-05	0.00129	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—sarcoma	7.48e-05	0.00129	CcSEcCtD
Gefitinib—Diarrhoea—Vincristine—sarcoma	7.4e-05	0.00127	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—sarcoma	7.34e-05	0.00126	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—sarcoma	7.28e-05	0.00125	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—sarcoma	7.26e-05	0.00125	CcSEcCtD
Gefitinib—Nausea—Thiotepa—sarcoma	7.24e-05	0.00125	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—sarcoma	7.23e-05	0.00124	CcSEcCtD
Gefitinib—Diarrhoea—Mitoxantrone—sarcoma	7.21e-05	0.00124	CcSEcCtD
Gefitinib—Nausea—Dactinomycin—sarcoma	7.19e-05	0.00124	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—sarcoma	7.16e-05	0.00123	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—sarcoma	7.16e-05	0.00123	CcSEcCtD
Gefitinib—ABCB1—hematopoietic system—sarcoma	7.15e-05	0.00176	CbGeAlD
Gefitinib—CYP1A1—liver—sarcoma	7.13e-05	0.00176	CbGeAlD
Gefitinib—Infestation NOS—Doxorubicin—sarcoma	7.12e-05	0.00122	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—sarcoma	7.12e-05	0.00122	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—sarcoma	7.06e-05	0.00121	CcSEcCtD
Gefitinib—CYP3A5—liver—sarcoma	6.98e-05	0.00172	CbGeAlD
Gefitinib—Urticaria—Etoposide—sarcoma	6.96e-05	0.0012	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—sarcoma	6.95e-05	0.00119	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—sarcoma	6.94e-05	0.00119	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—sarcoma	6.92e-05	0.00119	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—sarcoma	6.92e-05	0.00119	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—sarcoma	6.92e-05	0.00119	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—sarcoma	6.91e-05	0.00119	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—sarcoma	6.91e-05	0.00119	CcSEcCtD
Gefitinib—Vomiting—Vincristine—sarcoma	6.88e-05	0.00118	CcSEcCtD
Gefitinib—CYP2C9—liver—sarcoma	6.86e-05	0.00169	CbGeAlD
Gefitinib—Urinary tract disorder—Epirubicin—sarcoma	6.83e-05	0.00117	CcSEcCtD
Gefitinib—Rash—Vincristine—sarcoma	6.82e-05	0.00117	CcSEcCtD
Gefitinib—Dermatitis—Vincristine—sarcoma	6.81e-05	0.00117	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—sarcoma	6.81e-05	0.00117	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—sarcoma	6.79e-05	0.00117	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—sarcoma	6.77e-05	0.00116	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—sarcoma	6.74e-05	0.00116	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—sarcoma	6.72e-05	0.00116	CcSEcCtD
Gefitinib—Vomiting—Mitoxantrone—sarcoma	6.7e-05	0.00115	CcSEcCtD
Gefitinib—Rash—Mitoxantrone—sarcoma	6.64e-05	0.00114	CcSEcCtD
Gefitinib—Dermatitis—Mitoxantrone—sarcoma	6.63e-05	0.00114	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—sarcoma	6.53e-05	0.00112	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—sarcoma	6.46e-05	0.00111	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—sarcoma	6.45e-05	0.00111	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—sarcoma	6.43e-05	0.00111	CcSEcCtD
Gefitinib—Nausea—Vincristine—sarcoma	6.42e-05	0.0011	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—sarcoma	6.41e-05	0.0011	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—sarcoma	6.39e-05	0.0011	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—sarcoma	6.39e-05	0.0011	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—sarcoma	6.32e-05	0.00109	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—sarcoma	6.3e-05	0.00108	CcSEcCtD
Gefitinib—Asthenia—Etoposide—sarcoma	6.28e-05	0.00108	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—sarcoma	6.27e-05	0.00108	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—sarcoma	6.27e-05	0.00108	CcSEcCtD
Gefitinib—Nausea—Mitoxantrone—sarcoma	6.26e-05	0.00108	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—sarcoma	6.23e-05	0.00107	CcSEcCtD
Gefitinib—Pruritus—Etoposide—sarcoma	6.2e-05	0.00107	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—sarcoma	6.17e-05	0.00106	CcSEcCtD
Gefitinib—Alopecia—Epirubicin—sarcoma	6.11e-05	0.00105	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—sarcoma	6.05e-05	0.00104	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—sarcoma	6.02e-05	0.00103	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—sarcoma	5.99e-05	0.00103	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—sarcoma	5.98e-05	0.00103	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—sarcoma	5.93e-05	0.00102	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—sarcoma	5.8e-05	0.000998	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—sarcoma	5.76e-05	0.000991	CcSEcCtD
Gefitinib—ABCG2—lymph node—sarcoma	5.76e-05	0.00142	CbGeAlD
Gefitinib—Arrhythmia—Doxorubicin—sarcoma	5.71e-05	0.000982	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—sarcoma	5.65e-05	0.000972	CcSEcCtD
Gefitinib—Vomiting—Etoposide—sarcoma	5.57e-05	0.000958	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—sarcoma	5.57e-05	0.000957	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—sarcoma	5.56e-05	0.000956	CcSEcCtD
Gefitinib—Rash—Etoposide—sarcoma	5.52e-05	0.00095	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—sarcoma	5.52e-05	0.000949	CcSEcCtD
Gefitinib—CYP1A1—lymph node—sarcoma	5.47e-05	0.00135	CbGeAlD
Gefitinib—CYP2D6—testis—sarcoma	5.45e-05	0.00134	CbGeAlD
Gefitinib—Malaise—Epirubicin—sarcoma	5.43e-05	0.000933	CcSEcCtD
Gefitinib—ABCB1—uterus—sarcoma	5.4e-05	0.00133	CbGeAlD
Gefitinib—Cough—Epirubicin—sarcoma	5.25e-05	0.000903	CcSEcCtD
Gefitinib—CYP3A4—liver—sarcoma	5.23e-05	0.00129	CbGeAlD
Gefitinib—Nausea—Etoposide—sarcoma	5.2e-05	0.000895	CcSEcCtD
Gefitinib—CYP2D6—liver—sarcoma	5.15e-05	0.00127	CbGeAlD
Gefitinib—Anaemia—Doxorubicin—sarcoma	5.15e-05	0.000885	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	5.09e-05	0.000875	CcSEcCtD
Gefitinib—ABCB1—lymphoid tissue—sarcoma	5.04e-05	0.00124	CbGeAlD
Gefitinib—Malaise—Doxorubicin—sarcoma	5.02e-05	0.000863	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—sarcoma	5.01e-05	0.000861	CcSEcCtD
Gefitinib—Infection—Epirubicin—sarcoma	4.88e-05	0.000839	CcSEcCtD
Gefitinib—Cough—Doxorubicin—sarcoma	4.86e-05	0.000835	CcSEcCtD
Gefitinib—Shock—Epirubicin—sarcoma	4.83e-05	0.000831	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—sarcoma	4.82e-05	0.000828	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—sarcoma	4.81e-05	0.000827	CcSEcCtD
Gefitinib—Skin disorder—Epirubicin—sarcoma	4.77e-05	0.00082	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.71e-05	0.000809	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—sarcoma	4.68e-05	0.000805	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—sarcoma	4.64e-05	0.000797	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—sarcoma	4.59e-05	0.000789	CcSEcCtD
Gefitinib—ABCB1—bone marrow—sarcoma	4.58e-05	0.00113	CbGeAlD
Gefitinib—Infection—Doxorubicin—sarcoma	4.51e-05	0.000776	CcSEcCtD
Gefitinib—Shock—Doxorubicin—sarcoma	4.47e-05	0.000769	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—sarcoma	4.46e-05	0.000766	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—sarcoma	4.45e-05	0.000765	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—sarcoma	4.41e-05	0.000759	CcSEcCtD
Gefitinib—Dyspnoea—Epirubicin—sarcoma	4.38e-05	0.000753	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—sarcoma	4.33e-05	0.000745	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—sarcoma	4.27e-05	0.000734	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—sarcoma	4.25e-05	0.00073	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—sarcoma	4.24e-05	0.000729	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—sarcoma	4.23e-05	0.000728	CcSEcCtD
Gefitinib—Constipation—Epirubicin—sarcoma	4.2e-05	0.000722	CcSEcCtD
Gefitinib—Pain—Epirubicin—sarcoma	4.2e-05	0.000722	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—sarcoma	4.05e-05	0.000696	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—sarcoma	4.02e-05	0.00069	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—sarcoma	3.95e-05	0.000679	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—sarcoma	3.92e-05	0.000674	CcSEcCtD
Gefitinib—ABCB1—testis—sarcoma	3.92e-05	0.000967	CbGeAlD
Gefitinib—Fatigue—Doxorubicin—sarcoma	3.92e-05	0.000674	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—sarcoma	3.9e-05	0.000671	CcSEcCtD
Gefitinib—Pain—Doxorubicin—sarcoma	3.89e-05	0.000668	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—sarcoma	3.89e-05	0.000668	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—sarcoma	3.88e-05	0.000667	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—sarcoma	3.88e-05	0.000667	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—sarcoma	3.72e-05	0.000639	CcSEcCtD
Gefitinib—ABCB1—liver—sarcoma	3.71e-05	0.000914	CbGeAlD
Gefitinib—Hypersensitivity—Epirubicin—sarcoma	3.62e-05	0.000622	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—sarcoma	3.61e-05	0.000621	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—sarcoma	3.59e-05	0.000618	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—sarcoma	3.59e-05	0.000618	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—sarcoma	3.52e-05	0.000606	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—sarcoma	3.47e-05	0.000597	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—sarcoma	3.36e-05	0.000578	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—sarcoma	3.35e-05	0.000576	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—sarcoma	3.26e-05	0.000561	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—sarcoma	3.21e-05	0.000553	CcSEcCtD
Gefitinib—Vomiting—Epirubicin—sarcoma	3.12e-05	0.000537	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—sarcoma	3.11e-05	0.000535	CcSEcCtD
Gefitinib—Rash—Epirubicin—sarcoma	3.1e-05	0.000532	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—sarcoma	3.09e-05	0.000532	CcSEcCtD
Gefitinib—Nausea—Epirubicin—sarcoma	2.92e-05	0.000502	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—sarcoma	2.89e-05	0.000497	CcSEcCtD
Gefitinib—Rash—Doxorubicin—sarcoma	2.86e-05	0.000493	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—sarcoma	2.86e-05	0.000492	CcSEcCtD
Gefitinib—ABCB1—lymph node—sarcoma	2.84e-05	0.000701	CbGeAlD
Gefitinib—Nausea—Doxorubicin—sarcoma	2.7e-05	0.000464	CcSEcCtD
Gefitinib—ERBB3—Signaling Pathways—FOXO1—sarcoma	7.66e-06	0.000117	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFC—sarcoma	7.65e-06	0.000117	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PDGFRB—sarcoma	7.64e-06	0.000117	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—NRAS—sarcoma	7.62e-06	0.000117	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—sarcoma	7.57e-06	0.000116	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KRAS—sarcoma	7.57e-06	0.000116	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	7.54e-06	0.000115	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—PDGFRA—sarcoma	7.53e-06	0.000115	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIT—sarcoma	7.51e-06	0.000115	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—CTNNB1—sarcoma	7.43e-06	0.000114	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CREB1—sarcoma	7.29e-06	0.000112	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	7.23e-06	0.000111	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	7.22e-06	0.000111	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	7.16e-06	0.00011	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CREB1—sarcoma	7.15e-06	0.00011	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KRAS—sarcoma	7.15e-06	0.000109	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MDM2—sarcoma	7.11e-06	0.000109	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—KRAS—sarcoma	6.96e-06	0.000107	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—SRC—sarcoma	6.95e-06	0.000106	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—sarcoma	6.94e-06	0.000106	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IL2—sarcoma	6.93e-06	0.000106	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MDM2—sarcoma	6.79e-06	0.000104	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CCND1—sarcoma	6.76e-06	0.000103	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—JUN—sarcoma	6.74e-06	0.000103	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—SRC—sarcoma	6.72e-06	0.000103	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PLCG1—sarcoma	6.71e-06	0.000103	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF1R—sarcoma	6.7e-06	0.000103	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—HRAS—sarcoma	6.7e-06	0.000103	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—CTNNB1—sarcoma	6.69e-06	0.000102	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—NRAS—sarcoma	6.69e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—CTNNB1—sarcoma	6.64e-06	0.000102	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FOXO1—sarcoma	6.59e-06	0.000101	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PDGFRB—sarcoma	6.58e-06	0.000101	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	6.58e-06	0.000101	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KDR—sarcoma	6.57e-06	0.000101	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MDM2—sarcoma	6.56e-06	0.0001	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KRAS—sarcoma	6.56e-06	0.0001	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—HRAS—sarcoma	6.54e-06	0.0001	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—MDM2—sarcoma	6.52e-06	9.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—PDGFRA—sarcoma	6.48e-06	9.92e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	6.47e-06	9.91e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—NRAS—sarcoma	6.46e-06	9.89e-05	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—HRAS—sarcoma	6.43e-06	9.85e-05	CbGpPWpGaD
Gefitinib—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	6.4e-06	9.81e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FOXO1—sarcoma	6.38e-06	9.76e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PDGFRB—sarcoma	6.36e-06	9.75e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—IL2—sarcoma	6.35e-06	9.73e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KDR—sarcoma	6.33e-06	9.7e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	6.31e-06	9.66e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—PDGFRA—sarcoma	6.27e-06	9.59e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—JUN—sarcoma	6.18e-06	9.46e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—CTNNB1—sarcoma	6.13e-06	9.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FLT1—sarcoma	6.11e-06	9.36e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—sarcoma	6.09e-06	9.33e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—FOXO1—sarcoma	6.09e-06	9.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PDGFRB—sarcoma	6.08e-06	9.31e-05	CbGpPWpGaD
Gefitinib—MKNK1—Disease—HRAS—sarcoma	6.08e-06	9.31e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KIT—sarcoma	6.05e-06	9.27e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—SRC—sarcoma	6.05e-06	9.26e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MDM2—sarcoma	6.03e-06	9.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MYC—sarcoma	6.02e-06	9.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PLCG1—sarcoma	6.01e-06	9.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—SRC—sarcoma	6e-06	9.18e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PDGFRA—sarcoma	5.98e-06	9.16e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MDM2—sarcoma	5.92e-06	9.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—HRAS—sarcoma	5.92e-06	9.06e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—JUN—sarcoma	5.91e-06	9.04e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—VEGFA—sarcoma	5.89e-06	9.02e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—sarcoma	5.89e-06	9.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—CTNNB1—sarcoma	5.86e-06	8.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—VEGFA—sarcoma	5.84e-06	8.95e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KIT—sarcoma	5.84e-06	8.94e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—NRAS—sarcoma	5.82e-06	8.91e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.8e-06	8.88e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CXCR4—sarcoma	5.77e-06	8.84e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—NRAS—sarcoma	5.77e-06	8.84e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CREB1—sarcoma	5.76e-06	8.82e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KRAS—sarcoma	5.76e-06	8.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ATF1—sarcoma	5.71e-06	8.74e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.68e-06	8.69e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO2—sarcoma	5.66e-06	8.67e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—CTNNB1—sarcoma	5.66e-06	8.67e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HBA1—sarcoma	5.63e-06	8.62e-05	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—HRAS—sarcoma	5.58e-06	8.54e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KRAS—sarcoma	5.56e-06	8.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CREB1—sarcoma	5.55e-06	8.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—SRC—sarcoma	5.54e-06	8.49e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MYC—sarcoma	5.42e-06	8.3e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL2—sarcoma	5.39e-06	8.25e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	5.36e-06	8.21e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO2—sarcoma	5.35e-06	8.2e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—NRAS—sarcoma	5.33e-06	8.16e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HBA1—sarcoma	5.32e-06	8.14e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—sarcoma	5.3e-06	8.12e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—SRC—sarcoma	5.3e-06	8.11e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL2—sarcoma	5.29e-06	8.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KDR—sarcoma	5.27e-06	8.08e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CCND1—sarcoma	5.25e-06	8.05e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—JUN—sarcoma	5.24e-06	8.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—CREB1—sarcoma	5.23e-06	8.02e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—CTNNB1—sarcoma	5.2e-06	7.97e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—JUN—sarcoma	5.14e-06	7.88e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—SRC—sarcoma	5.12e-06	7.84e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—CTNNB1—sarcoma	5.1e-06	7.82e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—NRAS—sarcoma	5.1e-06	7.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—SRC—sarcoma	5.09e-06	7.79e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KIT—sarcoma	5.02e-06	7.69e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KRAS—sarcoma	5.01e-06	7.67e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—KRAS—sarcoma	4.97e-06	7.61e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—NRAS—sarcoma	4.92e-06	7.54e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—NRAS—sarcoma	4.89e-06	7.49e-05	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—HRAS—sarcoma	4.89e-06	7.49e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO2—sarcoma	4.88e-06	7.47e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KIT—sarcoma	4.86e-06	7.44e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—sarcoma	4.86e-06	7.44e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HBA1—sarcoma	4.85e-06	7.42e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PLCG1—sarcoma	4.81e-06	7.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CREB1—sarcoma	4.78e-06	7.32e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MDM2—sarcoma	4.77e-06	7.3e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.76e-06	7.3e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—HRAS—sarcoma	4.73e-06	7.24e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—SRC—sarcoma	4.7e-06	7.2e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KIT—sarcoma	4.64e-06	7.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CREB1—sarcoma	4.62e-06	7.08e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—SRC—sarcoma	4.61e-06	7.07e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MDM2—sarcoma	4.6e-06	7.04e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KRAS—sarcoma	4.59e-06	7.03e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MYC—sarcoma	4.59e-06	7.02e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—VEGFA—sarcoma	4.58e-06	7.01e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PLCG1—sarcoma	4.54e-06	6.95e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—NRAS—sarcoma	4.52e-06	6.93e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—sarcoma	4.48e-06	6.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1R—sarcoma	4.48e-06	6.86e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—sarcoma	4.45e-06	6.81e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—NRAS—sarcoma	4.44e-06	6.8e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CREB1—sarcoma	4.42e-06	6.76e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KRAS—sarcoma	4.39e-06	6.72e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO2—sarcoma	4.38e-06	6.71e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HBA1—sarcoma	4.35e-06	6.66e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—sarcoma	4.27e-06	6.55e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FOXO1—sarcoma	4.26e-06	6.53e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL2—sarcoma	4.26e-06	6.52e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PDGFRB—sarcoma	4.26e-06	6.52e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—HRAS—sarcoma	4.26e-06	6.52e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HBA1—sarcoma	4.25e-06	6.5e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KRAS—sarcoma	4.24e-06	6.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—HRAS—sarcoma	4.22e-06	6.46e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MYC—sarcoma	4.21e-06	6.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KRAS—sarcoma	4.21e-06	6.45e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—PDGFRA—sarcoma	4.19e-06	6.42e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CCND1—sarcoma	4.15e-06	6.36e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—JUN—sarcoma	4.14e-06	6.35e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PLCG1—sarcoma	4.14e-06	6.34e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—sarcoma	4.12e-06	6.31e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—CTNNB1—sarcoma	4.11e-06	6.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL2—sarcoma	4.11e-06	6.29e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—sarcoma	4.04e-06	6.19e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—sarcoma	4.03e-06	6.17e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CCND1—sarcoma	4e-06	6.13e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HBA1—sarcoma	4e-06	6.13e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—JUN—sarcoma	3.99e-06	6.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—sarcoma	3.99e-06	6.12e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HBA1—sarcoma	3.97e-06	6.08e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—CTNNB1—sarcoma	3.96e-06	6.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MDM2—sarcoma	3.96e-06	6.06e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—HRAS—sarcoma	3.9e-06	5.97e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KRAS—sarcoma	3.89e-06	5.96e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL2—sarcoma	3.88e-06	5.95e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL2—sarcoma	3.87e-06	5.93e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MDM2—sarcoma	3.83e-06	5.86e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KRAS—sarcoma	3.82e-06	5.85e-05	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—HRAS—sarcoma	3.73e-06	5.71e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SRC—sarcoma	3.72e-06	5.69e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PLCG1—sarcoma	3.72e-06	5.69e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MDM2—sarcoma	3.65e-06	5.59e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PLCG1—sarcoma	3.63e-06	5.55e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—VEGFA—sarcoma	3.62e-06	5.54e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—HRAS—sarcoma	3.6e-06	5.51e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SRC—sarcoma	3.58e-06	5.49e-05	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—HRAS—sarcoma	3.58e-06	5.48e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—NRAS—sarcoma	3.58e-06	5.48e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL2—sarcoma	3.54e-06	5.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KDR—sarcoma	3.53e-06	5.4e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—VEGFA—sarcoma	3.49e-06	5.34e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—sarcoma	3.46e-06	5.3e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—NRAS—sarcoma	3.45e-06	5.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—JUN—sarcoma	3.44e-06	5.27e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL2—sarcoma	3.42e-06	5.24e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PLCG1—sarcoma	3.42e-06	5.23e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—CTNNB1—sarcoma	3.41e-06	5.23e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SRC—sarcoma	3.39e-06	5.19e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PLCG1—sarcoma	3.39e-06	5.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CCND1—sarcoma	3.33e-06	5.1e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MYC—sarcoma	3.33e-06	5.1e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—JUN—sarcoma	3.33e-06	5.09e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—HRAS—sarcoma	3.31e-06	5.07e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—VEGFA—sarcoma	3.3e-06	5.06e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—CTNNB1—sarcoma	3.3e-06	5.05e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—NRAS—sarcoma	3.26e-06	4.99e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	3.26e-06	4.99e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—sarcoma	3.25e-06	4.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—NRAS—sarcoma	3.25e-06	4.97e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—HRAS—sarcoma	3.25e-06	4.97e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MYC—sarcoma	3.21e-06	4.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—CTNNB1—sarcoma	3.15e-06	4.83e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—sarcoma	3.14e-06	4.81e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CREB1—sarcoma	3.09e-06	4.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—SRC—sarcoma	3.09e-06	4.72e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	3.08e-06	4.71e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SRC—sarcoma	2.98e-06	4.57e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—NRAS—sarcoma	2.97e-06	4.55e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KRAS—sarcoma	2.97e-06	4.54e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	2.91e-06	4.45e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—NRAS—sarcoma	2.87e-06	4.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—SRC—sarcoma	2.85e-06	4.36e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—KRAS—sarcoma	2.81e-06	4.3e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—KRAS—sarcoma	2.8e-06	4.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—NRAS—sarcoma	2.74e-06	4.2e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—sarcoma	2.74e-06	4.19e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MYC—sarcoma	2.67e-06	4.09e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—sarcoma	2.64e-06	4.04e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—sarcoma	2.63e-06	4.03e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HBA1—sarcoma	2.62e-06	4.01e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	2.62e-06	4.01e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—sarcoma	2.61e-06	4e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—sarcoma	2.56e-06	3.92e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KRAS—sarcoma	2.55e-06	3.91e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MYC—sarcoma	2.55e-06	3.91e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—HRAS—sarcoma	2.52e-06	3.86e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—sarcoma	2.49e-06	3.82e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KRAS—sarcoma	2.47e-06	3.78e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—HRAS—sarcoma	2.39e-06	3.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—HRAS—sarcoma	2.38e-06	3.64e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KRAS—sarcoma	2.36e-06	3.61e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL2—sarcoma	2.29e-06	3.5e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PLCG1—sarcoma	2.23e-06	3.42e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CCND1—sarcoma	2.23e-06	3.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—sarcoma	2.22e-06	3.41e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—CTNNB1—sarcoma	2.21e-06	3.38e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—sarcoma	2.2e-06	3.36e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—HRAS—sarcoma	2.17e-06	3.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—HRAS—sarcoma	2.1e-06	3.22e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—HRAS—sarcoma	2e-06	3.07e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SRC—sarcoma	1.99e-06	3.05e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—VEGFA—sarcoma	1.94e-06	2.98e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—NRAS—sarcoma	1.92e-06	2.94e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MYC—sarcoma	1.79e-06	2.74e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KRAS—sarcoma	1.65e-06	2.53e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—sarcoma	1.47e-06	2.25e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—HRAS—sarcoma	1.4e-06	2.15e-05	CbGpPWpGaD
